Gain-of-function RHOA mutations promote focal adhesion kinase activation and dependency in diffuse gastric cancer by Zhang, H. et al.
Gain-of-Function RHOA Mutations Promote Focal Adhesion 
Kinase Activation and Dependency in Diffuse Gastric Cancer
Haisheng Zhang1,2,*, Antje Schaefer3,4,*, Yichen Wang2, Richard G. Hodge3, Devon R. 
Blake4, J. Nathaniel Diehl5, Alex G. Papageorge8, Matthew Stachler2, Jennifer Liao2, Jin 
Zhou2, Zhong Wu2, Fahire Akarca2, Leonie K. de Klerk2, Sarah Derks2, Mariaelena 
Pierobon11, Katherine A. Hoadley3,5,6, Timothy C. Wang9, George Church12, Kwok-Kin 
Wong10, Emanuel F. Petricoin11, Adrienne D. Cox3,4,7, Douglas R. Lowy8, Channing J. 
Der3,4,5,#, Adam J. Bass2,13,#
1Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 
China
2Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical 
School, Boston, MA, USA
3Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel 
Hill, NC, USA
4Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
5Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, 
Chapel Hill, NC, USA
6Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
7Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 
USA
8Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, 
Bethesda, MD, USA
9Division of Gastroenterology, Columbia University Medical Center, New York, NY, USA
10Division of Hematology and Oncology, New York University, New York, NY, USA
11Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George 
Mason University, Manassas, VA, USA
Correspondence to Adam J. Bass, M.D., Dana-Farber Cancer Institute, 450 Brookline Ave; Dana 810B, Boston, MA 02215, 
617-632-2477, (adam_bass@dfci.harvard.edu), Or Channing J. Der, Ph.D., Lineberger Comprehensive Cancer Center, University of 
North Carolina at Chapel Hill, Chapel Hill, NC 27514, 919-966-5634 (channing_der@med.unc.edu).
*These authors contributed equally
#These authors contributed equally
Authors’ Contributions
A.J.B., H.Z., C.J.D., A.S. and D.R.L. designed the study and experiments. A.J.B., C.J.D., E.F.P., T.C.W., and D.R.L. provided 
resources and critical input. K.K.W oversaw generation of the novel murine allele. Methodology: A.S., R.G.H., D.R.B. and J.N.D. 
conducted the biochemical and cell culture experiments, A.G.P. performed metabolic labeling, H.Z. and Y.W. performed the organoid 
experiments, M.P. performed the RPPA studies and H.Z.,Y.W., J.L. and J.Z. conducted the in vivo experiments. Formal Analyses: 
A.S., R.G.H. and D.R.B. conducted the biochemical analyses, J.N.D. analyzed the RPPA results. M.S. and A.F. provided pathology 
expertise. L.K. and S.D. provided human DGC samples for the IHC staining. Writing – Original Draft, A.J.B., H.Z., A.S., R.G.H., 
K.A.H., J.N.D., A.D.C. and C.J.D.; Writing – Review & Editing, A.J.B., H.Z., A.S., R.G.H., D.R.B., A.D.C., D.R.L.,G.C. and C.J.D.
HHS Public Access
Author manuscript
Cancer Discov. Author manuscript; available in PMC 2020 August 01.
Published in final edited form as:
Cancer Discov. 2020 February ; 10(2): 288–305. doi:10.1158/2159-8290.CD-19-0811.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
12Harvard, MIT, Blavatnik Inst., Wyss Inst., Boston, MA, USA
13Broad Institute of MIT and Harvard, Cambridge, MA, USA
Abstract
Diffuse gastric cancer (DGC) is a lethal malignancy lacking effective systemic therapy. Among the 
most provocative recent results in DGC has been that of highly recurrent missense mutations in the 
GTPase RHOA. The function of these mutations has remained unresolved. We demonstrate that 
RHOAY42C, the most common RHOA mutation in DGC, is a gain-of-function oncogenic mutant 
and that expression of RHOAY42C with inactivation of canonical tumor suppressor Cdh1 induces 
metastatic DGC in a mouse model. Biochemically, RHOAY42C exhibits impaired GTP hydrolysis 
and enhances interaction with its effector ROCK. RHOAY42C mutation and Cdh1 loss induce 
actin/cytoskeletal rearrangements and activity of focal adhesion kinase (FAK), which activates 
YAP/TAZ, phosphoinositide 3-kinase (PI3K)/AKT and β-catenin. RHOAY42C murine models 
were sensitive to FAK inhibition and to combined YAP and PI3K pathway blockade. These results, 
coupled to sensitivity to FAK inhibition in patient-derived DGC cell lines, nominate FAK as a 
novel target for these cancers.
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INTRODUCTION
Gastric cancer (GC), the third leading cause of cancer death world-wide (1), is classically 
divided into two histologic types, intestinal and diffuse (2). Histologically, diffuse GC 
(DGC) is notable for the frequent appearance of mucin-filled ‘signet-ring’ cells, highly 
invasive and poorly differentiated cancer cells, lack of cellular cohesion (3), and an invasive 
growth pattern that contributes to rapid invasion and peritoneal metastases. Molecularly, 
DGCs largely fall into Genomically Stable molecular group, tumors typically lacking 
hypermutation and chromosomal instability (4). The absence of mutations in conventional 
oncoproteins and uncertainty over mechanisms of transformation in DGC have hindered 
therapeutic development. The most specific genomic aberration in sporadic DGC, whether 
through mutation (5) or methylation (6,7), is somatic inactivation of the tumor suppressor 
gene CDH1, which encodes the adhesion protein E-cadherin. In hereditary DGC, CDH1 is 
inactivated in the germline (8,9). More recently, genomic characterization by our group and 
others (3,4,10–12) identified missense mutations of RAS homologous (RHOA) small 
GTPase in 15–26% of DGC.
Like RAS, RHOA cycles between inactive, GDP-bound and active GTP-bound 
conformations, the latter of which interacts with downstream effectors to regulate the actin 
cytoskeleton, cell migration, cytokinesis and the cell cycle (13). Yet, RHOA missense 
mutations in DGC occur at residues distinct from conventional activating mutations found in 
RAS (Supplementary Fig. S1A). Neither the consequences of these mutations for RHOA 
activity nor their impacts on disease pathogenesis have been clearly established. Studies of 
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RHOA mutations in DGC have reached conflicting conclusions. Kakiuchi et al. described 
recurrent RHOA mutations as gain-of-function; siRNA-mediated silencing of RHOA 
reduced proliferation in non-DGC cancer cells harboring RHOA mutations (3). In contrast, 
Wang et al. suggested that RHOAY42C is a loss-of-function mutant, as ectopic RHOAY42C 
attenuated GTP-levels, inferred from cell-based pulldown analyses using the RHOA-GTP 
binding domain (RBD) of Rhotekin (10).
In this study, we characterized the RHOAY42C mutation via extensive biochemical analyses 
and detailed investigation of its activity in gastric epithelium using a genetically-engineered 
mouse model (GEMM). We demonstrate that recurrent genomic alterations found in DGC, 
CDH1 loss coupled with RHOAY42C, induces metastatic DGC in mice resembling the 
human disease. Using detailed biochemistry, we established that the Y42C mutation 
activates RHOA, impairing GTP hydrolysis and promoting RHOA interaction with ROCK, 
and enhancing actin rearrangements and focal adhesion formation. Furthermore, we 
demonstrate that Cdh1 loss and RHOAY42C induce DGC via activation of focal adhesion 
kinase (FAK), promoting activation of YAP/TAZ, PI3K/AKT and β-catenin, thereby 
identifying therapeutic approaches for DGC. FAK inhibition abrogates tumor growth in our 
novel model and shows efficacy across a broader panel of patient-derived DGC cell lines, 
suggesting that FAK may serve as a potent therapeutic target for these cancers.
RESULTS
Cdh1 Loss with RHOA-Y42C Induces Diffuse Gastric Cancer In Vivo
Given the lack of DGC cell lines harboring RHOA mutations, we chose to study RHOA 
mutation in the gastric lineage by establishing a murine model, LSL-RHOAY42C (using 
Y42C, the most recurrent RHOA mutation in DGC, Supplementary Fig. S1A), with RHOA 
Y42C engineered into the Col1A1 locus where its expression is activated by Cre recombinase 
(Fig. 1A). We introduced the Mist1-CreERT2 allele to express tamoxifen-activated Cre in 
the Mist1 locus, a marker of gastric chief cells suggested to be expressed in isthmus stem 
cells (14–16). To represent the most common genomic aberration in DGC, loss of CDH1, we 
used a conditional Cdh1 allele, Cdh1Flox/Flox. Finally, the R26-mTmG ‘Tomato-GFP’ allele 
was introduced to mark Cre-recombined cells by conversion from Tomato (red) to GFP 
(green). We bred cohorts of mice where we could inducibly express RHOAY42C in gastric 
epithelium and inducibly inactivate Cdh1, either alone or in combination.
While we aged mice following in vivo induction of Cre activity, we developed murine 
gastric organoids to evaluate RHOAY42C activity. Recombination was induced in the 
organoids in vitro via tamoxifen or adenoviral Cre-recombinase, and validated by conversion 
of Tomato to GFP expression (Fig. 1A), immunoblotting and immunofluorescence 
(Supplementary Fig. S1B–S1E). Following induction, we observed dramatic morphologic 
changes and induction of mesenchymal markers (Fig. 1B and C; Supplementary Fig. S1D–
S1F and Supplementary Video S1) in organoids expressing RHOAY42C in the absence of 
Cdh1 (Cdh1−/−RHOAY42C/+: Mist1-CreERT2, Cdh1Flox/Flox, LSL-RHOAY42C/+), but not 
with RHOAY42C/+ alone (RHOAY42C/+: Mist1-CreERT2, LSL-RHOAY42C/+) or Cdh1 loss 
alone (Cdh1−/−: Mist1-CreERT2, Cdh1Flox/Flox). Whereas Cdh1−/− or RHOAY42C/+ 
organoids retained spherical forms with hollow interiors, Cdh1−/−RHOAY42C/+ organoids 
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exhibited abnormal morphology and central filling (Fig. 1B and C), a phenotype associated 
with transformation and consistent with morphologies of patient-derived DGC organoids 
(12,17). Histologic review identified signet-ring cells, a characteristic feature of DGC, in 
Cdh1−/−RHOAY42C/+ organoids (Fig. 1D; Supplementary Fig. S1G).
To determine if these organoids were transformed, we transplanted them (5×105 cells) via 
surgical injection into gastric walls of NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (Fig. 
1E). Mice implanted with Cdh1−/−RHOAY42C/+ organoids formed tumors and exhibited 
peritoneal spread, ascites and metastases to lung and liver (Fig. 1F and G). By contrast, no 
tumors formed with Cdh1−/− or RHOAY42C/+ or Mist1Cre control organoids. Accordingly, 
survival analysis showed that mice implanted with Cdh1−/−RHOAY42C/+ organoids 
succumbed rapidly whereas survival was not decreased in other groups (Fig. 1H). We 
obtained analogous results following subcutaneous flank injections (Supplementary Fig. 
S1H and S1I).
We then evaluated autochthonous expression of RHOAY42C in mice aged for 14 months 
after in vivo tamoxifen induction. Tumors were identified in the stomachs only of 
Cdh1−/−RHOAY42C/+ mice (5/8 mice, 62.5%; Supplementary Fig. S1J). These results 
recapitulate those showing that Mist1-CreERT2, Cdh1Flox/Flox mice do not develop tumors 
unless infected with Helicobacter felis (16). Histologic analysis confirmed that 
Cdh1−/−RHOAY42C/+ tumors were poorly differentiated with cells resembling signet-ring 
cells (Supplementary Fig. S1K). These results establish RHOAY42C as an oncogene that, 
with Cdh1 loss, induces tumors resembling human DGC.
RHOAY42C Exhibits A Gain-of-Function Phenotype In Vitro
We next characterized consequences of the Y42C mutation for RHOA function by assessing 
its effect on RHOA-regulated cellular activities. Seminal studies establishing involvement of 
RHOA in regulating actin cytoskeletal organization, cell adhesion and migration utilized lab-
generated, constitutively-activated RHOA mutants (G14V, Q63L; analogous to RAS 
residues G12 and Q61) expressed in NIH/3T3 mouse fibroblasts and related 3T3 cell lines 
(18,19). To evaluate the activity of RHOAY42C relative to extensive literature evaluating 
RHOA variants in NIH/3T3 cells we established NIH/3T3 cells stably expressing exogenous 
RHOAY42C protein at levels comparable to exogenous RHOAWT or RHOAQ63L 
(Supplementary Fig. S2A and S2B). NIH/3T3 fibroblasts are mesenchymal cells lacking 
expression of the epithelial cell-restricted CDH1 gene.
RHOA promotes actin stress fibers, which are important for cell morphology and adhesion. 
As we described previously (20), RHOAQ63L enhanced stress fiber formation compared with 
RHOAWT (Fig. 2A and B). RHOAY42C also enhanced stress fiber formation, at a level 
intermediate between Q63L and WT, indicating that Y42C causes a gain-of-function 
phenotype with respect to this canonical RHOA function.
RHOA also stimulates focal adhesions (FA) assembly, protein complexes that connect the 
actin cytoskeleton with the extracellular matrix (21,22) We investigated the ability of 
RHOAY42C to regulate FA assembly in NIH/3T3 cells, utilizing the Focal Adhesion 
Analysis Server. Both RHOAQ63L and RHOAY42C but not RHOAWT increased FA size 
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(area, Fig. 2C). Conversely, RHOAWT reduced the numbers of FA per cell, whereas 
RHOAY42C did not (Fig. 2D). RHOAQ63L but not RHOAWT enhanced FA eccentricity 
(deviation from a circular shape, Fig. 2E). Although the increase did not reach statistical 
significance, RHOAY42C also enhanced FA eccentricity (Fig. 2E). We conclude that like 
RHOAQ63L, RHOAY42C exhibits a gain-of-function phenotype with respect to FA assembly.
We next evaluated the ability of RHOAY42C to regulate cell-matrix adhesion. As previously 
reported, RHOAQ63L impaired adhesion to fibronectin (Fig. 2F). Surprisingly, RHOAWT 
also impaired adhesion, whereas RHOAY42C did not. Thus, the effect of RHOAY42C on 
adhesion differs from both WT and Q63L. Actin stress fiber and FA organization regulate 
cell migration (22). As shown previously (23,24), RHOAQ63L impaired the velocity (Fig. 
2G) and directionality of migration (Supplementary Fig. S2C). In contrast, RHOAY42C-
expressing cells showed similar migration velocity and directionality as WT.
We then evaluated these findings in our murine gastric organoids, in which we could induce 
Cdh1 loss and/or RHOAY42C expression (overview of models used in this study in 
Supplementary Table S1). Immunofluorescence microscopy studies revealed increased F-
actin levels in RHOAY42C/+ organoids (especially in Cdh1−/−RHOAY42C/+ organoids) 
compared to Mist1Cre or Cdh1−/− organoids (Fig. 2H), consistent with our NIH/3T3 results 
(Fig. 2A and B).
Overall, our studies of actin- and FA-mediated cell adhesion and migration show that 
RHOAY42C causes a gain-of-function phenotype that does not simply phenocopy lab-
generated constitutively-activated mutant RHOAQ63L. It has been a puzzle as to why RHOA 
mutations analogous to RAS are not found in cancer. Our results suggest a possible clue: the 
lab-generated RHOAQ63L mutant may reduce actin dynamics by overly increasing stress 
fiber formation thus decreasing rather than increasing motility. In contrast, RHOAY42C may 
optimally increase both stress fiber formation and motility to more effectively engage the 
actin cytoskeleton in a pro-transformation manner.
RHOAY42C Exhibits Impaired GTP Hydrolysis and Altered Effector Binding
We next determined the mechanistic basis for the gain-of-function biochemical Y42C 
phenotype. We initially hypothesized that, like the cancer-associated RAC1b splice variant 
that is impaired in RhoGDI1 interaction (25), the Y42C mutation impairs RHOA interaction 
with RhoGDI1, a regulator of membrane association and subcellular localization (13). We 
ectopically co-overexpressed HA-epitope-tagged RHOA and GFP-tagged RhoGDI1 in 
COS-7 cells, immunoprecipitated HA-RHOA, and immunoblotted for GFP. In agreement 
with previous studies (26,27), we found that RHOAWT but not active RHOAQ63L or the 
RHOAT19N dominant-negative mutant associated with RhoGDI1 (Supplementary Fig. S2D 
and S2E). However, RHOAY42C binding to RhoGDI1 was similar to that of RHOAWT. 
Consistent with this, RHOAY42C and RHOAWT displayed similar subcellular localization in 
NIH/3T3 cells (Supplementary Fig. S2F). We conclude that Y42C does not alter RHOA 
interaction with RhoGDI1.
We next hypothesized that Y42C imparts a fast-cycling phenotype, like the gain-of-function, 
cancer-associated P29S mutation in the small GTPase RAC1 (28). We purified E. coli-
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expressed recombinant RHOA proteins and measured intrinsic nucleotide exchange using a 
fluorescence-labelled-nucleotide assay. However, activities of RHOA WT and Y42C were 
not significantly different (Fig. 3A). Thus, Y42C does not alter GDP-GTP cycling.
To evaluate Y42C interaction with GEFs, we evaluated TCGA data for expression of RHO 
family GEFs and GAPs in gastric cancer (Supplementary Fig. S3A). The RHOA-selective 
GEF ECT2 is preferentially upregulated in GC compared to adjacent normal tissue 
(Supplementary Fig. S3B). ECT2 overexpression is associated with GC progression and 
poor prognosis (29). Therefore, we tested the ability of recombinant ECT2 C-terminal DH-
PH domain (catalytic GEF fragment) to stimulate nucleotide exchange on WT and mutant 
RHOA. ECT2-catalyzed nucleotide exchange activities on RHOAWT and RHOAY42C were 
similar to each other (kcat = 23.3 × 10−4 s−1 and 21.1 × 10−4 s−1, respectively, Fig. 3B; 
Supplementary Fig. S3C), and to activities described for other RhoGEFs (30), indicating that 
Y42C does not alter GEF sensitivity.
Activating RAS mutations (e.g., Q61L) impair intrinsic and GAP-stimulated GTP 
hydrolysis, thereby favoring the active, GTP-bound form. We directly measured GTP bound 
to recombinant RHOA proteins in HPLC assays. The intrinsic GTP hydrolysis rate, which 
was completely abolished by the Q63L mutation (Fig. 3C and D), was reduced 440-fold in 
RHOAY42C relative to RHOAWT (0.05 × 10−5 s−1 and 22.1 × 10−5 s−1, respectively). To 
verify this striking GTPase deficiency, we also applied a fluorescence-based hydrolysis 
assay using a phosphate-binding-protein sensor, which confirmed that intrinsic GTP 
hydrolysis is greatly impaired in RHOAY42C (Fig. 3E and F). Finally, since Y42C is located 
in the switch I region of RHOA, which is also involved in GAP binding, we performed 
precise biochemical assays to determine whether Y42C alters GAP activation. Using 
recombinant protein (catalytic domain only) of the RHOA-specific GAP p190RhoGAP/
ARHGAP35, expressed at high levels in GC (Supplementary Fig. S3A), we found that GAP-
stimulated catalytic activity of RHOAY42C was reduced 4-fold relative to RHOAWT (kcat = 
2.6 × 10−2 s−1 and 10.4 × 10−2 s−1, respectively; Fig. 3G; Supplementary Fig. S3D). These 
results indicate that reductions in both intrinsic and GAP-stimulated GTP hydrolysis favor 
increased levels of RHOAY42C-GTP.
To directly measure the guanine nucleotide bound to RHOAY42C in living cells, we adapted 
the classic method of 32P-orthophosphate metabolic labeling developed originally for RAS. 
Unlike the standard pulldown assay that detects only relative levels of RHOA-GTP (21), the 
32P radiolabeling assay enables precise quantitation of the percentage of RHOA bound to 
GTP or GDP. As expected, RHOA WT was predominantly GDP-bound (only 1.8% GTP-
bound; Fig. 3H; Supplementary Fig. S3E), whereas RHOAQ63L was predominantly (78%) 
GTP-bound. Surprisingly, despite its impaired GTP hydrolysis, Y42C showed a reproducible 
but not statistically significant increase in GTP binding (3.2%) compared to RHOAWT. This 
result suggests that additional alterations other than those tilting the balance of GTP to GDP 
contribute to the ability of RHOAY42C to stimulate canonical RHOA functions such as actin 
stress fiber and FA formation.
Y42 lies in RHOA’s effector domain. Studies performed prior to discovery of RHOA 
mutations in DGC showed that a Y42C substitution generated in cis with RAS-like 
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activating RHOA mutations (G14V or Q63L) altered RHOA effector interactions (31,32). 
However, how Y42C alone impacts effector interactions has not been determined. ROCK 
and mDia are RHOA effector proteins regulating F-actin dynamics (33), and Rhotekin-RBD 
is the standard pulldown reagent used to determine RHOA-GTP levels in cells (21). 
Utilizing a well-established fluorescence-based effector interaction assay, we found that the 
binding affinities between recombinant RHOAWT and the isolated RBDs of Rhotekin (500 
± 40 nM), ROCK (380 ± 30 nM) and mDia (460 ± 60 nM) were similar to each other 
(Supplementary Fig. S3F) and comparable to previous studies (34,35). In contrast, whereas 
RHOAY42C binding to mDia-RBD was comparable to that of RHOAWT, its binding to 
ROCK-RBD was increased 12-fold (Fig. 3I; Supplementary Fig. S3F). Unexpectedly, 
RHOAY42C did not bind to Rhotekin-RBD, indicating that the standard Rhotekin-RBD 
pulldown assay does not accurately measure GTP levels of Y42C. Mechanistically, since 
ROCK promotes actin stress fiber formation, whereas Rhotekin has been reported to 
antagonize it (36), the enhanced ROCK binding of RHOAY42C together with loss of 
Rhotekin binding provides further basis for its gain-of-function phenotype observed in stress 
fiber formation assays (Fig. 2A and B). Additionally, since ROCK enhances FA formation 
(37), increased ROCK binding may contribute to the gain-of-function phenotype of 
RHOAY42C in our FA studies. Taken together with its impaired intrinsic and GAP-
stimulated GTP hydrolysis, we demonstrated that RHOAY42C is a gain-of-function mutant 
due to alterations in both GDP-GTP regulation and effector interactions (see model, Fig. 3J). 
These results suggest a biochemical basis for RHOAY42C serving as a driver of DGC in our 
mouse model.
RHOAY42C Promotes Activation of PI3K/AKT, β-catenin and YAP/TAZ
Having established that RHOAY42C is an oncogene, we next evaluated the signaling and 
cellular effects of RHOAY42C expression in the gastric lineage. We established a isogenic 
organoids from the gastric epithelia of Cdh1Flox/Flox mice (Supplementary Fig. S4A and 
S4B). We introduced ectopic EGFP-RHOAY42C, EGFP-RHOAQ63L, EGFP-RHOAWT or 
EGFP control via lentiviral transduction and created either Cdh1-null or WT models by 
using adenoviral Cre recombinase. These organoids were then evaluated by Reverse Phase 
Protein Array (RPPA) analyses to evaluate the consequences of genetic alterations on global 
signaling. Analyses revealed increased phosphorylation of diverse signaling proteins in 
Cdh1-null organoids expressing RHOAY42C compared to RHOAWT (Supplementary Fig. 
S4C and Supplementary Table S2). These differences were markedly increased in Cdh1-null 
compared to isogenic Cdh1 WT organoids. Consistent with our biochemical and cellular 
analyses, RPPA identified ROCK activation in Cdh1-null organoids expressing RHOAY42C 
compared to RHOAWT (Fig. 4A; Supplementary Fig. S4D). Increased activation of PI3k-
AKT-mTORC1 signaling in Cdh1-null RHOAY42C expressing organoids was also observed 
(Fig. 4A; Supplementary Fig. S4E). AKT phosphorylation at S473 and T308 were two of the 
most significantly upregulated phosphorylation sites in Cdh1-null organoid with exogenous 
RHOAY42C versus RHOAWT (Fig. 4B). Many significant changes found in Cdh1-null 
organoids were not observed with Cdh1 WT organoids (Fig. 4C), suggesting that signaling 
required to induce tumor formation is dependent on both Cdh1 loss and RHOAY42C 
expression (Fig. 1).
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Interestingly, the EGFP-RHOAQ63L vector could not be expressed in Cdh1 intact organoids. 
Although Cdh1-null organoids expressing RHOAQ63L showed the same increased AKT 
phosphorylation at S473 as with RHOAY42C, the overall signaling profile was distinct 
(Supplementary Fig. S4F and S4G). These findings together with our biochemical and 
cellular studies may provide evidence for why RHOAQ63L is not found in cancer.
Because of the RPPA results, we focused on further evaluation of AKT signaling. 
Immunoblotting confirmed that AKT was not activated in Cdh1-null organoids unless 
RHOAY42C was also expressed (Fig. 4D). Under those conditions, we also observed elevated 
phosphorylation of AKT target Gsk3β at S9 (Fig. 4D), which downregulates destruction of 
β-catenin by the Gsk3β/Axin/APC complex (38–40). Immunoblotting also demonstrated 
that β-catenin abundance was markedly attenuated in Cdh1−/− compared to Cdh1+/+ 
organoids and was not altered upon expression of RHOAWT (Fig. 4D). In contrast, 
RHOAY42C increased β-catenin expression in Cdh1-null organoids. E-cadherin tethers β-
catenin to the cell membrane. Thus, we hypothesized that the combination of GSK3β 
repression and loss of Cdh1/E-cadherin enables nuclear translocation β-catenin in 
Cdh1−/−RHOAY42C/+ organoids. Indeed, these organoids displayed elevated nuclear β-
catenin in vitro and following orthotopic implantation (Fig. 4E; Supplementary Fig. S4H–
S4J). We further validated that downstream targets of β-catenin, c-Myc and Cyclin D1 were 
upregulated by RHOAY42C expression (Supplementary Fig. S4K). To investigate the 
relationship of AKT activation and β-catenin induction, we ectopically expressed the 
constitutively-activated mutant PI3KαH1074R (PIK3CAH1074R) in Cdh1-null organoids and 
observed increased levels of pAKT and active β-catenin (Supplementary Fig. S4L). 
Conversely, pharmacologic blockade of PI3K (with pictilisib) or AKT (with MK-2206) 
suppressed the TOP/FOP Wnt/β-catenin reporter in Cdh1−/−RHOAY42C/+ organoids 
(Supplementary Fig. S4M). These data demonstrate that, in the setting of Cdh1 loss, RHOA-
mediated PI3K activation promotes β-catenin activation.
We next sought additional mediators of RHOA’s oncogenic activity. RHOA mediates 
activation of YAP/TAZ (41,42), which interacts with β-catenin (43). We found expressing 
RHOAY42C in Cdh1-null organoids increased YAP and TAZ expression (Fig. 4F) and active, 
non-phosphorylated form YAP (Fig. 4G), suggesting that YAP/TAZ signaling is activated in 
Cdh1−/−RHOAY42C/+ organoids. As RHOAY42C activates both β-catenin and YAP/TAZ 
signaling, we evaluated whether activation of these pathways replaces RHOAY42C in 
mediating transformation of Cdh1-null gastric organoids. Although expression of either 
active YAP(S127A) (Supplementary Fig. S4N) or β-catenin(S33Y) alone failed to induce 
tumor growth, combination of both YAP(S127A) and β-catenin(S33Y) induced robust tumor 
formation (Fig. 4H) with cells resembling signet ring cells both in vitro and following 
xenograft growth (Supplementary Fig. S4O and S4P).
YAP/TAZ and β-catenin Pathways Are both Required for Cdh1−/−RHOAY42C/+-Induced 
Transformation
We next investigated whether the YAP/TAZ and β-catenin pathways are necessary for 
RHOAY42C oncogenicity. We first targeted these pathways with genetic tools in 
Cdh1−/−RHOAY42C/+ organoids, using the YAP dominant negative mutant S94A (YAP-DN, 
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Supplementary Fig. S5A) and a dominant negative mutant of β-catenin cofactor TCF4 
(TCF4-DN, aa 1–31 del; Supplementary Fig. S5B). Although only YAP-DN inhibited 
organoid growth in vitro, both attenuated the aberrant organoid morphology (Supplementary 
Fig. S5C and S5D). Importantly, either YAP-DN or TCF4-DN dramatically inhibited tumor 
growth in vivo (Fig. 5A–B; Supplementary Fig. S5E). Histological analyses showed that 
small tumors formed following expression of YAP-DN or TCF4-DN displayed less 
resemblance to DGC and instead displayed greater gland formation and differentiation (Fig. 
5C). To determine if YAP-DN or TCF4-DN also inhibit organoid-derived gastric cancer 
models that were not driven by Cdh1 loss and RHOAY42C, we utilized a model generated 
from Trp53−/−KrasG12D/+ mice (44). We found only modest effects on tumor growth and in 
vitro proliferation of Trp53−/−KrasG12D/+ organoids similarly engineered to express YAP-
DN and/or TCF4-DN (Fig. 5D; Supplementary Fig. S5F), demonstrating that targeting these 
pathways did not induce nonspecific toxicity. Overall, these data suggest that the YAP/TAZ 
and β-catenin/TCF4 pathways are necessary and sufficient to drive tumor formation in the 
Cdh1−/−RHOAY42C/+ gastric model.
We next explored the therapeutic potential of pharmacologically targeting these pathways in 
Cdh1−/−RHOAY42C/+ organoids. We targeted the AKT/β-catenin axis with ICG-001, an 
antagonist of β-catenin cofactor TCF4, or with AKT inhibitor MK-2206, both of which 
attenuated aberrant organoid morphology and had modest but significant effects on viability 
(Supplementary Fig. S5G–S5I). Similarly, YAP pathway inhibitor verteporfin had modest 
effects on organoid proliferation (Supplementary Fig. S5I). Further testing suggested that 
pharmacological inhibition of single pathways led to adaptive changes in other pathways, 
which may mitigate responses to single drug treatment (Supplementary Fig. S5J). 
Specifically, YAP/TAZ inhibition induced pAKT; conversely, AKT inhibition enhanced TAZ 
expression. Accordingly, the combination of verteporfin with either ICG-001 or MK-2206 
markedly inhibited proliferation and induced apoptosis in the Cdh1−/−RHOAY42C/+ model 
(Fig. 5E and F; Supplementary Fig. S5G), whereas the same treatments had only modest 
effects on organoids from Trp53−/−KrasG12D/+ mice (Fig. 5E and F; Supplementary Fig. S5I 
and S6A). We also tested these combinations in normal and Cdh1−/− organoids, finding only 
a modest effect relative to their effects in the Cdh1−/−RHOAY42C/+ model (Supplementary 
Fig. S5K and S5L).We next tested these combinations in vivo in the transplanted Cdh1−/− 
RHOAY42C/+ model. Instead of ICG-001, we inhibited the PI3K/AKT pathway, given the 
availability of drugs in advanced clinical development. Our in vitro studies showed that 
PI3K inhibitor pictilisib, which inhibits AKT, to be superior to MK-2206 (Supplementary 
Fig. S6B and S6C). We therefore selected pictilisib for in vivo combination with verteporfin. 
Both verteporfin and pictilisib individually inhibited tumor growth, and we saw greater 
effects with the combination (Fig. 5G; Supplementary Fig. S6D), suggesting clinical 
potential for combined PI3K/AKT- and YAP/TAZ-directed therapy in RHOA-mutant DGC.
RHOAY42C-mediated FAK activation induces PI3K/AKT and YAP/TAZ
We next investigated the more proximal means by which RHOAY42C activates pathways 
including PI3K/AKT and YAP/TAZ. We hypothesized that Focal Adhesion Kinase (FAK) 
could mediate these activities because RHOAY42C induces FA assembly and actin 
rearrangements, and activates PI3K/AKT signaling. FAK signaling has been described to 
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regulate FA dynamics, actin reorganization and PI3K/AKT signaling to drive invasion and 
metastasis and to contribute to RHOA activity in multiple cancers (45,46). Large-scale 
proteomic studies also implicated FAK-mediated pathways in human DGC (46,47). Our 
RPPA analyses revealed increased phosphorylation of FAK substrates (as pFAK was not in 
the RPPA panel) such as receptor tyrosine kinase Ret (48) in Cdh1-null organoids expressing 
RHOAY42C (Fig. 4B).
By immunoblotting, we confirmed enhanced FAK activation upon RHOAY42C expression in 
Cdh1-null organoids (Fig. 6A), and in Cdh1−/−RHOAY42C/+ organoids (Fig. 6B; 
Supplementary Fig. S7A). Similarly, ectopic expression of WT PTK2 (encoding FAK) in 
Cdh1-null organoids increased both pAKT and active YAP levels (Fig. 6C; Supplementary 
Fig. S7B). Furthermore, immunoprecipitation studies showed that FAK co-
immunoprecipitated with PI3KCA in Cdh1−/−RHOAY42C/+ organoids, indicating that FAK 
directly activates PI3K (Supplementary Fig. S7C). These results are consistent with studies 
on FAK-mediated PI3K/AKT activation controlling actin cytoskeletal remodeling and FA 
formation in multiple cancers (45,46). In addition, FAK also induced aberrant morphology 
in these organoids (Fig. 6D), recapitulating features seen with RHOAY42C, including mucin 
production which contributes to signet ring cell formation (Fig. 6E).
We then evaluated genetic and pharmacologic targeting of FAK in Cdh1−/− RHOAY42C/+ 
models. shRNA-mediated silencing of Ptk2 (FAK) reduced pAKT and active YAP (Fig. 6F; 
Supplementary Fig. S7D). Silencing of Ptk2 (FAK) reverted the morphology of 
Cdh1−/−RHOAY42C/+ organoids but had little effect on Trp53−/−KrasG12D/+ organoids 
(Supplementary Fig. S7E). We next evaluated pharmacologic FAK inhibition. PF-573228, a 
small molecule FAK inhibitor, attenuated activation of AKT, YAP and β-catenin (Fig. 6G; 
Supplementary Fig. S7F–S7H). PF-573228 treatment dramatically reversed the aberrant 
Cdh1−/−RHOAY42C/+ morphology (Fig. 6H) in a dose-dependent manner (Supplementary 
Fig. S7I) and decreased staining with Ki67 (Supplementary Fig. S7J) and Alcian Blue, a 
marker of mucin formation (Fig. 6I). Live-cell confocal imaging demonstrated that 
PF-573228 normalized the morphology of Cdh1−/−RHOAY42C/+ organoids over 
approximately 30 hours (Fig. 6J; Supplementary Video S2).
FAK Inhibition Abrogates both In Vitro Proliferation and In Vivo Tumor Growth
We next further explored FAK as a DGC therapeutic target. FAK inhibitor PF-573228 
markedly decreased proliferation in Cdh1−/−RHOAY42C/+ but not Trp53−/−KrasG12D/+ 
gastric organoids in vitro (Supplementary Fig. S7K and S7L), indicating FAK as specific 
target in our DGC model. We also found lack of efficacy in FAK inhibition in normal gastric 
organoids but greater effects of FAK inhibition in Cdh1−/− organoids, (Supplementary Fig. 
S7M–N) consistent with our finding of modestly enhanced pFAK following Cdh1 loss 
(Supplementary Fig. S7O).Relatedly, PF-573228 abrogated tumor growth of 
Cdh1−/−RHOAY42C/+ organoid xenografts (Fig. 6K). To validate our findings, we tested the 
clinical candidate FAK inhibitor, defactinib, and obtained similar results in vitro and in vivo 
(Fig. 6L; Supplementary Fig. S7P–S7R). To further characterize effects of FAK inhibition, 
we performed Ki67 and TUNEL staining of Cdh1−/−RHOAY42C/+ organoid xenografts, 
finding evidence of both diminished proliferation and apoptosis induction (Fig. 6M–N). 
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Taken together, these results establish FAK as a mediator of RHOAY42C function in DGC 
pathogenesis and establish this kinase as a promising candidate target (Fig. 6O).
FAK Is A Potent Therapeutic Target in Human DGC Cell Lines and Patients
We next evaluated FAK inhibition in human DGC cell line models. Although there are no 
DGC cell lines with endogenous RHOA mutation, RHOA activity has been demonstrated to 
be elevated in existing DGC cell lines relative to intestinal gastric cancer (IGC) models (49). 
Utilizing immunoblotting, we verified enhanced FAK activation in DGC lines compared to 
IGC lines (Fig. 7A and B). We checked E-cadherin in these DGC lines and found them 
either lacking E-cadherin expression (SNU668 and FU97) or possess CDH1 mutation 
(NUGC4 with CDH1, p.D257V) while IGC cell lines had markedly higher E-cadherin 
expression (Supplementary Fig. S8A). To further confirm our hypothesis that RHOA 
promotes FAK activation, we silenced RHOA using siRNA and observed attenuated pFAK 
levels (Supplementary Fig. S8B). We also found that FAK inhibitors PF-573228 and 
defactinib attenuated pFAK and pAKT levels in the DGC cell lines FU97 and SNU668, but 
not in IGC-line SNU719, which lacks evident pFAK (Fig. 7C). Furthermore, DGC lines 
were sensitive to PF-573228 treatment in vitro while IGC cells were insensitive (Fig. 7D and 
E). In DGC PF-573228 induced G2-M cell cycle arrest (Supplementary Fig. S8C) in dose-
dependent manner (Supplementary Fig. S8D). We next compared in vivo growth of DGC 
SNU668 and IGC SNU719 cell lines. We found that DGC SNU668 tumor growth was 
inhibited by PF-573228 treatment, but had minimal response to 5-flourouracil (5-FU), a 
commonly used agent in DGC (Fig. 7F and G). In contrast, IGC line SNU719 showed 
markedly greater sensitivity in vivo to 5-FU compared to PF-5732228 (Fig. 7H; 
Supplementary Fig. S8E). PF-573228 treatment not only attenuated proliferation 
(Supplementary Fig. S8F), but also induced DNA damage and apoptosis of SNU668 in vivo 
(Supplementary Fig. S8G–S8H), consistent with data from organoids (Fig. 6M and 6N).
To further investigate FAK in DGC, we evaluated FAK activation in DGC surgical samples 
using immunohistochemistry, finding pFAK staining in 17 of 18 evaluated samples, with 
FAK staining in 70%−100% of tumor cells compared to negative staining in surface 
epithelial cells and minimal staining in normal glandular epithelial cells (Fig. 7I; 
Supplementary Fig. S8I). We also evaluated the level of pFAK in 8 non-DGC samples and 
observed positive staining in only one case (Supplementary Fig. S8J). These data provide 
support for the potential relevance of FAK in DGC beyond that observed in our engineered 
murine model.
DISCUSSION
Genomic studies of DGC have found that the two most characteristic classes of alterations 
affect cellular adhesion (e.g., CDH1 and CLND18) and RHO signaling (e.g., RHOA and 
ARHGAP26) (4,12,50,51). However, these findings have yet to be translated to deeper 
functional understanding of disease pathogenesis or therapeutically. Whether RHOA 
mutations represent activating or inactivating alterations has remained uncertain. The 
specific residues recurrently mutated contributed to this uncertainty. RHOAY42C is 
analogous to Y40C in RAS, an effector domain mutant impairing interaction of RASG12V 
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with RAF (52). Following these studies in RAS, RHOA Y42C had been studied in cis with 
activating RHOA mutations (G14V or Q63L) as an experimental strategy to attribute RHOA 
functions to specific RHOA effectors (31,32). Thus, when RHOA Y42C mutations were 
identified in DGC, it was unexpected that a putative loss-of-effector-function mutant could 
serve as an oncogene, fueling discussion whether RHOA serves as a tumor suppressor 
(3,10). Our analyses provide demonstrate RHOAY42C to be an oncogene. Similar to 
RHOAG14V/Q63L, RHOAY42C exhibits an activated phenotype, stimulating actin stress fiber 
formation and FA assembly, albeit at a reduced potency. Interestingly, RHOAY42C did not 
simply phenocopy RHOAQ63L but instead exhibited distinct activities in regulation of cell 
adhesion and migration, and signaling. That RHOAQ63L suppressed, whereas RHOAY42C 
stimulated, migration is consistent with our finding that RHOAY42C promotes DGC that is 
invasive and metastatic.
By studying RHOAY42C without secondary mutations, we found impaired intrinsic and 
GAP-stimulated GTP hydrolysis activity, properties favoring formation of active GTP-bound 
RHOA. However, these biochemical defects did not drive significant steady-state 
accumulation of RHOA-GTP in cells. Our analyses of effector binding revealed additional 
alterations: increased affinity for ROCK, the key effector that drives RHOA stimulation of 
actin stress fibers and FA assembly, and loss of binding to Rhotekin, an effector that 
antagonizes actin stress fiber formation. Together, these altered effector interactions provide 
a mechanistic explanation for the RHOAY42C gain-of-function phenotype, stimulating FA 
assembly and activation of FAK. Additionally, loss of Rhotekin binding explains why 
standard Rhotekin-RBD pulldown assays (21) would produce misleading results for 
RHOAY42C activation.
Our murine gastric model provides further validation that RHOAY42C is an oncogene. That 
oncogenic function was unmasked with loss of E-cadherin may explain why RHOA 
mutations are restricted to cancers arising from a very limited spectrum of tissue types. 
These results also suggest a functional interaction of RHOA and E-cadherin. Our data 
suggest gastric CDH1 loss alone does not promote invasive cancer (16,53). Indeed, cells 
with CDH1 loss are more prone to undergo anoikis (54), a checkpoint whereby cells 
undergo apoptosis upon loss of attachment (55). In vivo, Cdh1−/− gastric epithelial cells 
were lost over time (16). Cell-cell adhesion (promoted by E-cadherin) suppresses anoikis by 
activating PI3K/AKT and other pathways (56), a model consistent with our results that 
pAKT was attenuated in gastric organoids following Cdh1 inactivation (Fig. 4D). The ability 
of RHOAY42C to activate the PI3K pathway may enhance survival and tumorigenicity of 
Cdh1-null gastric cells, via both activation of pAKT and β-catenin. These data suggest that 
PI3K/AKT inhibition could be used to block Wnt/ β-catenin signaling. However, further 
studies would be needed to fully evaluate the effects of PI3K/AKT inhibition in DGC given 
the potential for induction of FOXO3a with these agents to have tumor promoting effects 
(57). It is notable that the other tumor type associated with germline CDH1 loss, lobular 
breast cancer, possesses recurrent co-occurrence of CDH1 and PIK3CA mutations (58). 
PIK3CA mutations are less common in DGC, whereas breast cancers lack recurrent RHO 
alterations. This unique selection for RHOA dysregulation in DGC suggests the importance 
of a PI3K- and β-catenin-independent pathway. Additionally, it is the case that not all 
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RHOA mutant DGCs harbor detectable CDH1 mutations, raising the question of what other 
alterations may collaborate with RHOA mutation.
Our results showing RHOA/FAK-mediated activation of PI3K and YAP/TAZ could explain 
the DGC predilection for RHOA mutation. Many studies have implicated RHOA and the 
actin cytoskeleton as upstream activators of YAP/TAZ (41,42,59). We validated the 
activation of YAP/TAZ in gastric cells transformed by RHOAY42C and Cdh1 loss. 
Aberrations of the actin cytoskeleton are commonly seen in cancer (60), and enhanced F-
actin rearrangement with RHOAY42C likely provides even greater mechanical stimulus for 
YAP/TAZ activation. YAP also confers resistance to chemotherapeutic agents in ovarian 
cancer (61) and oral squamous cell carcinoma (62), suggesting that YAP may contribute to 
the poor efficacy of cytotoxic therapy in DGC.
Humar et al. found that although pFAK was not present in early pre-neoplastic foci in 
patients with hereditary DGC, FAK became activated in more advanced lesions (53), 
consistent with our findings that activating FAK with Cdh1 loss promotes progression. 
Furthermore, our results establish a contribution of FAK signaling to DGC pathogenesis and 
demonstrate a mechanistic connection between RHOA and FAK with activation of PI3K/
AKT, β-catenin and YAP/TAZ. Whether FAK activation is more ubiquitously essential with 
CDH1 loss is not established. The sensitivity we observed of DGC cell lines to FAK 
inhibition implies that FAK may serve as a target for DGCs including those without RHOA 
mutation. Indeed, CDH1 silencing was shown to sensitize mesothelioma cells to FAK 
inhibition (63), suggesting a potential role for FAK blockade more broadly in CDH1-null 
cancers.
In summary, these data address uncertainties following discovery of RHOA mutations in 
DGC. Our biochemical studies establish RHOAY42C as a gain-of-function mutation that 
modulates RHOA interaction with downstream effectors. These data demonstrate how 
aberrant RHOA activation collaborates with loss of tumor suppressor CDH1 to stimulate 
signaling networks that mediate transformation (see model, Fig.6O), leading to features 
typical of the disease, including signet ring cell formation, peritoneal spread and ascites. 
Furthermore, these models reveal how PI3K activation promotes nuclear β-catenin 
localization in CDH1-null gastric cells by attenuating GSK3β-mediated β-catenin 
destruction. Our data also demonstrate that FAK activation is a mediator of both PI3K/AKT-
β-catenin and YAP activity, secondary to RHOAY42C mutations. These data and models 
provide a new foundation for mechanistic and translational inquiry into these deadly cancers 
where progress has languished, and where treatments continue to be reliant on minimally 
effective cytotoxic therapy.
METHODS
Generation of Mouse Cohorts
We generated a mouse allele with inducible expression of RHOAY42C. The human RHOA 
cDNA coding region with the Kozak sequence (GCCGCCACC) was introduced into vector 
pGV at the EcoRI cloning site using blunt-end cloning. Sequencing-confirmed pGV-
RHOAY42C vectors were co-electroporated with plasmid expressing FLP recombinase into 
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mouse ES cells (MESC10, Mirimus) engineered with a FLP homing cassette at Co1A1 
locus, and positive clones were identified by PCR. Positive ES clones were injected into 
mouse blastocysts for chimera generation. Chimeric mice were crossed with wildtype mice 
to generate mice with germline mutations. A detailed strategy was previously described (64). 
The gene is expressed following Cre recombinase-mediated excision of a stop cassette 
flanked by LoxP sites (loxP-stop-loxP (LSL) RHOAY42C/+). Mist1-CreERT2, Cdh1Flox/ Flox, 
R26-mTmG mice were developed as previously published (16). Mist1-CreERT2, 
Cdh1Flox/ Flox, R26-mTmG mice were crossed with LSL-RHOAY42C/+ mice to generate 
Mist1-CreERT2, Cdh1Flox/ Flox, LSL-RHOAY42C/+, R26-mTmG mice; genotyping was 
confirmed with appropriate primers (See Supplementary Table S3). All animals were 
maintained and used in accordance with the guidelines of the Institutional Animal Care and 
Use Committee of the Dana-Farber Cancer Institute.
Cell Lines
NIH/3T3 mouse fibroblasts were obtained originally from Dr. Geoffrey M. Cooper (Dana-
Farber Cancer Institute) and COS-7 cells and HEK293T cells were obtained from ATCC 
(American Type Culture Collection). Cells were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% calf serum (NIH/3T3) or fetal bovine serum 
(FBS, COS-7 and HEK293T), penicillin and streptomycin. Cell lines were passaged for one 
month or 10 passages before a new aliquot was thawed. Cell lines were monitored monthly 
for mycoplasma contamination using the Lonza MycoAlertTM Mycoplasma Detection Kit 
and not authenticated. SNU668, NUGC4, AGS and SNU719 were from Broad Institute and 
maintained in RPMI-1640 supplemented with 10% fetal bovine serum. FU97 was from 
Broad Institute and maintained in DMEM supplemented with 10% fetal bovine serum and 
10 mg/L insulin (Sigma). These cells were authenticated by Broad Institute. Isogenic 
MCF10 cell lines (CDH1-WT/KO) were purchased from Sigma and maintained in MEGM 
(Lonza). The isogenic MCF10 cells were authenticated by western blot with E-cadherin 
antibody. All cell lines were maintained in a humidified chamber with 5% CO2 at 37°C. 
Cells were monitored regularly for mycoplasma contamination.
Orthotopic Transplantation
Prior to orthotopic transplantation, organoids were collected and dissociated to 
approximately single cells using TrypLE Express (Life Technologies). Approximately 5×105 
cells were resuspended in 50 μl of a mixture of Matrigel and media (1:1). NSG mice (6–8 
weeks old, The Jackson Laboratory) were sedated using isoflurane inhalation anesthesia. 
The stomach was exteriorized through a midline abdominal incision and the 50 μl of cell 
suspension was surgically injected into the stomach wall with all care to avoiding stomach 
puncture. The incision was immediately closed using a running 7–0 polypropylene suture 
(Prolene, Ethicon). The presence of tumors was evaluated by twice weekly abdominal/
stomach palpation. All animal experiments were conducted in accordance with protocols 
approved by the Institutional Animal Care and Use Committee at the Dana-Farber Cancer 
Institute, in compliance with NIH guidelines.
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HPLC GTP Hydrolysis Assay
To measure directly the intrinsic GTP hydrolysis, 70 μM RHOA-GTP was incubated at 25°C 
in 50 mM HEPES pH 7.5, 100 mM NaCl, 5 mM MgCl2, 5% glycerol and 5 mM β-
mercaptoethanol. Aliquots of 40 μl were flash frozen in liquid nitrogen at indicated time 
points to stop the reaction and incubated for 2 min at 95°C. After centrifugation (14,000 x g, 
1 min) of the denatured protein, the supernatant was applied to a high-performance liquid 
chromatography column (HPLC, Agilent 1100). GDP and GTP were separated on a C18-
column (Agilent) with 100 mM potassium-phosphate pH 6.5, 10 mM tert-butyl-ammonium-
bromide and 7.5% acetonitrile as mobile phase (65). The concentration of non-hydrolyzed 
GTP was plotted against time. Data were described by a mono-exponential equation to 
determine the observed rate constant (kobs) using GraphPad Prism. A similar protocol was 
used to measure the efficiency of RHOA nucleotide loading (25% acetonitrile for mant-
nucleotides).
Chemicals and Drugs
See Supplementary Table S4.
Antibodies
See Supplementary Table S5.
Reverse Phase Protein Microarray (RPPA)
RPPA analysis was performed in triplicate on gastric organoids harboring various Cdh1 and 
RHOA genetic perturbations. Samples were lysed as previously described (66). Cell lysates 
from organoids were immobilized onto nitrocellulose-coated glass slides (Grace Bio-labs) 
using an Aushon 2470 arrayer (Aushon BioSystems) in biological triplicates along with 
reference standards for quality control. Selected arrays were stained with Sypro Ruby 
Protein Blot Stain following manufacturer’s instructions to quantify the amount of protein in 
each sample. Immunostaining was performed as previously described (66). Clustering by 
antibodies was performed using k-means clustering. Fold change values represented were 
calculated with respect to the corresponding RHOA-EV control median intensity value by 
Cdh1 status and subsequently log2 changed, unless otherwise noted. Testing between 
specific comparisons utilized the Student’s T-test with p-values < 0.05 denoting significant 
alterations. Testing results were represented by volcano plots and/or reported in 
supplementary tables. Heatmaps were generated in R using the ComplexHeatmap package 
from Bioconductor.
Live-cell Confocal Imaging
Mouse organoids expressing GFP (R26-mTmG after tamoxifen induction) were cultured in 
conditioned media in a Lab-Tek II Chambered Coverglass system dish. Images of organoids 
with different genotypes were captured on an LSM 510 Meta live-cell confocal microscope, 
with GFP autofluorescence images taken every ten min for a total of 36–48 h of culture. For 
PF-573228 treatment, Cdh1−/−RHOAY42C/+GFP organoids were collected and dissociated 
into single cells using TrypLE Express, then plated into the same coverglass system at a 
density of 40,000 cells/25 μL Matrigel, and cultured for 2 days prior to treatment with 
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DMSO or PF-573228 (5 μM). Live-cell imaging was started immediately after drug 
treatment.
Statistical Analysis
Data are represented as mean ± S.D. or S.E.M. as indicated in the figure legends. For each 
experiment, the number of independent biological experiments are as noted in the figure 
legends, with representative images shown of replicates with similar results. Statistical 
analysis was performed using Microsoft Office statistical tools or in Prism 7.0 (GraphPad). 
Pairwise comparisons between groups (that is, experimental versus control) were performed 
using an unpaired two-tailed Student’s t-test, one-way ANOVA Tukey’s multiple 
comparison test, or two-way ANOVA as appropriate. P < 0.05 is considered to be 
statistically significant. P-values are denoted by *P < 0.05, **P < 0.01, ** P < 0.001, ****P 
< 0.0001. For all experiments, the variance between comparison groups was found to be 
equivalent. Sample sizes and animal numbers were determined from pilot laboratory 
experiments and previously published literature. Animals were excluded from analysis if 
they were euthanized due to health reasons unrelated to tumor growth. For in vivo 
experiments, all mice were randomized before drug treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SIGNIFICANCE
The functional significance of recurrent RHOA mutations in DGC has remained 
unresolved. Through biochemical studies and mouse modeling of the hotspot RHOAY42C 
mutation we establish that these mutations are activating, detail their effects upon cell 
signaling and define how RHOA-mediated FAK activation imparts sensitivity to 
pharmacologic FAK inhibitors.
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Figure 1. Cdh1 loss with RHOA hotspot mutation induces diffuse gastric cancer in vivo.
A, Schematic for the generation of mice with distinct genotypes, including the tomato-GFP 
reporter allele; bottom: representative stack confocal image of gastric organoids with 
Mist1CreERT2-R26mTmG 48 hours after tamoxifen (2 μM) induction in vitro. 
Representative images of (B) phase contrast and (C) H&E for gastric organoids with 
annotated genotypes after three weeks following in vitro tamoxifen induction. Scale bar = 
100 μm. D, Representative higher-magnification image showing signet ring cells in 
Cdh1−/−RHOAY42C/+organoids following tamoxifen induction. Scale bar = 50 μm. E, 
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Procedure of orthotopic injection into gastric wall with green arrow noting location 
following injection. F, Representative gross images of mouse with gastric tumor, ascites, 
peritoneal spread with liver metastases at eight weeks following orthotopic injection of 
Cdh1−/−RHOAY42C/+ organoids. G, Representative H&E images of liver and lung 
metastases following orthotopic implantation of Cdh1−/−RHOAY42C/+ organoids. Scale bar 
= 100 μm. H, Kaplan-Meier survival curve following orthotopic implantation of organoids 
of noted genotypes. Log-rank (Mantel-Cox) test, P=0.0047 (Cdh1−/−RHOAY42C/+ versus 
other genotypes).
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Figure 2. RHOAY42C is a mutation with gain-of-function by stimulating stress fibers and focal 
adhesions.
A, Immunofluorescence analysis of NIH/3T3 fibroblasts stably expressing exogenous HA 
epitope-tagged RHOA WT and mutant proteins, stained with phalloidin to monitor stress 
fiber formation and anti-vinculin antibody to visualize focal adhesions (FA). Images are 
representative of three independent experiments. Scale bar = 10 μm. B, Quantitation of stress 
fiber formation in the cells from (A), by calculating the corrected total cell fluorescence (20 
cells per condition, n = 3 independent experiments). To measure FA assembly in the cells 
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from (A), the area of each FA (C), the number of FA per cell (D), and the eccentricity of 
each FA (E) was calculated based on the vinculin staining (1307 to 2295 FA in 14 to 20 cells 
per condition, n = 3). Data are mean ± S.E.M. F, CMFDA-labelled NIH/3T3 cells were 
allowed to adhere upon fibronectin for 1 h. Data are mean ± S.E.M. (n = 3). G, Images of 
cells during random migration were captured using a time lapse microscope at 1 frame/10 
min for 16 h. Data are mean migration velocities ± S.E.M. (n = 4, 25 cells per experiment); 
***P<0.001, **P<0.01, *P<0.05, ns, not significant; P values from one-way ANOVA with 
Tukey’s multiple comparison test. H, Representative immunofluorescence images for F-
actin in organoids from mice with annotated genotypes. Phalloidin (in red) was used to 
visualize F-actin, DAPI (in blue) for the nucleus. Scale bar = 50 μm.
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Figure 3. RHOAY42C exhibits impaired GTP hydrolysis and altered effector binding.
A, E. coli-expressed RHOA proteins were evaluated in vitro. Intrinsic guanine nucleotide 
exchange activity (n = 3). B, Recombinant ECT2 DH-PH catalytic domain stimulation of 
RHOA nucleotide exchange activity (n = 3). Intrinsic RHOA GTP hydrolysis activity was 
determined by (C, D) directly measuring RHOA bound GTP levels (n = 4) or (E, F) based 
on phosphate release using the phosphate binding protein sensor (n = 2). G, Determination 
of p190RhoGAP catalytic domain stimulation of RHOA GTP hydrolysis activity using the 
phosphate binding protein sensor (n = 2). Data in A-G are mean ± S.E.M.; ***P<0.001, 
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**P<0.01, *P<0.05, ns, not significant; unpaired t-test. H, RHOA guanine nucleotide 
binding was determined in NIH/3T3 cells expressing the indicated RHOA proteins by 32P-
metabolic labeling (n = 2). Data are mean ± S.E.M., ***P<0.001, ns, not significant; one-
way ANOVA with Tukey’s multiple comparison test. I, Normalized binding affinities of 
RHOA WT and Y42C to RBD domains of indicated effectors, as determined in effector-
nucleotide dissociation assays; nb = binding too weak to be detected (n = 3). All affinities 
were normalized to RHOA WT binding to each effector. Data are mean ± S.E.M.; 
***P<0.001, ns, not significant; unpaired t-test. J, Comparison of WT and mutant RHOA 
biochemical properties.
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Figure 4. RHOAY42C promotes activation of PI3K/β-catenin and YAP/TAZ.
A, Heatmap representation of selected antibodies from RPPA analysis of isogenic gastric 
organoids with annotated genotypes. Cdh1+/+ and Cdh1−/− fold change values were 
calculated with respect to matched RHOA-EV controls per antibody (see also 
Supplementary Fig. S4A, S4D, S4E and Supplementary Table S1). Resulting values were 
log2 changed and clustered using k-means clustering for antibodies. B-C, Volcano plots 
representing results comparing RHOAY42C versus RHOAWT in (B) Cdh1-null organoids or 
(C) in Cdh1 WT organoids by RPPA analysis. Significantly upregulated and downregulated 
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proteins and phosphorylation sites are represented by pink and gold dots, respectively. 
Horizontal dotted line represents p-value threshold of 0.05. The list of top protein 
phosphorylation/expression differences is provided in Supplementary Table S1. D, 
Immunoblots of Cdh1 intact and null isogenic organoids engineered with lentiviral EGFP-
RHOAY42C or controls (representative image from 3 independent experiments). E, 
Immunofluorescence analysis of β-catenin in organoids from mice with annotated genomes. 
Scale bar = 100 μm. F, Immunoblotting for YAP in Cdh1-null organoids with lentiviral 
EGFP-RHOAY42C or controls (representative image from 3 independent experiments). G, 
Immunofluorescence of active (non-phosphorylated) YAP in organoids from mice of 
annotated genomes. Scale bar = 100 μm. H, Tumor incidence of Cdh1-null organoids with 
ectopic expression of YAP(S127A) or β-catenin(S33Y) or both vectors, implanted into 
flanks of NSG mice. Data are mean ± S.D; ****P<0.0001, unpaired two-tailed Student’s t-
test.
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Figure 5. YAP and β-catenin pathways are both required for the Cdh1−/−RHOAY42C/+-induced 
transformation.
A, Tumor volume of Cdh1−/−RHOAY42C/+ organoids with ectopic expression of either 
TCF4-DN (del aa 1–31) or YAP-DN (S94A) followed by flank implantation, with 
representative images (bottom) of tumors from each group (n=4 for each). Data are mean ± 
S.E.M. ****P<0.0001, two-way ANOVA, (TCF4-DN or YAP-DN versus EV group). B, 
Representative images of Ki67 staining of the tumors from (A). Scale bar = 50 μm. C, 
Representative H&E images for the tumors from (A). Scale bar = 100 μm. D, Tumor volume 
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of Trp53−/−KrasG12D/+ organoids with ectopic expression of TCF4-DN (del aa 1–31) or 
YAP-DN (S94A) or combination, implanted into flanks, with representative images of 
tumors from each group (n = 4 for each). Data are mean ± S.E.M. E, In vitro proliferation of 
Cdh1−/−RHOAY42C/+ and Trp53−/−KrasG12D/+ organoids treated with DMSO or verteporfin 
(YAP inhibitor, 5 μM) combined with ICG-001 (antagonist of β-catenin/TCF4 binding, 5 
μM) or MK-2206 (AKT inhibitor, 2 μM) for 48 h. Data are mean ± S.E.M. *P<0.05, 
***P<0.001, unpaired two-tailed Student’s t-test. F, Representative phase contrast images of 
Cdh1−/−RHOAY42C/+ or Trp53−/−KrasG12D/+ organoids treated for 48 h with DMSO or 
verteporfin (5 μM), combined with ICG-001 (5 μM) or MK-2206 (2 μM). Scale bar = 100 
μm. G, Tumor volume of Cdh1−/−RHOAY42C/+ organoids injected into flanks of NSG mice 
and treated with DMSO, pictilisib (PI3K inhibitor, 75 mg/kg), verteporfin (100 mg/kg) or 
the combination (n = 8 tumors for each). Data are mean ± S.E.M. **P<0.01, ****P<0.0001, 
two-way ANOVA (treatment versus DMSO).
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Figure 6. RHOAY42C-mediated FAK Activation Induces PI3K/AKT and YAP/TAZ.
A, Representative immunoblotting and quantitation of Cdh1−/− organoids with ectopic 
expression of RHOAY42C, RHOAWT or EGFP control (n = 3 independent experiments). B, 
Representative immunoblotting of gastric organoids with noted genotypes (n = 3 
independent experiments). C, Immunoblotting of Cdh1−/− organoids with ectopic expression 
of Ptk2 (FAK) or vector control (n = 3 independent experiments). Representative images of 
H&E (D) and Alcian Blue (E) for Cdh1−/− organoids with ectopic expression of Ptk2 or 
vector control. Scale bar = 100 μm. F, Immunoblotting of Cdh1−/−RHOAY42C/+ organoids 
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with silencing of Ptk2 or control (n= 3 independent experiments). G, Immunoblotting of 
Cdh1−/−RHOAY42C/+ organoids treated with DMSO or PF-573228 (1 μM and 5 μM) for 48 
h (n= 3 independent experiments). Representative images of (H) H&E and (I) Alcian Blue 
staining of Cdh1−/−RHOAY42C/+ organoids treated with DMSO or PF-573228 (5 μM) for 48 
h. Scale bar = 100 μm. J, Images from live-cell confocal microscopy of 
Cdh1−/−RHOAY42C/+ organoids treated with DMSO or PF-573228 (5 μM), with time from 
drug administration marked for each image. Scale bar = 20 μm. K, Tumor volume of 
Cdh1−/−RHOAY42C/+ organoids injected into flanks of NSG mice (n = 10 tumors per arm) 
treated with DMSO or PF-573228 (12.5 mg/kg), with representative images (right) of 
tumors. ***P<0.001, ****P<0.0001, unpaired two-tailed Student’s t-test. Data are mean ± 
S.E.M. L, Tumor volume of Cdh1−/−RHOAY42C/+ organoids injected into flanks of NSG 
mice (n = 10), randomly separated into 2 groups and treated with DMSO or defactinib (12.5 
mg/kg) every other day. ****P<0.0001, two-way ANOVA (defactinib versus DMSO). Data 
are mean ± S.E.M. M, Representative images of Ki67 staining of tumors from (K) and (L). 
Scale bar = 100 μm. N, Representative images of TUNEL staining of tumors from (K) and 
(L). Scale bar = 100 μm. O, Model of the signaling network induced by the gain-of-function 
mutation RHOAY42C and loss of Cdh1 (E-cadherin) in DGC. Targeted inhibitors are 
depicted in red boxes.
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Figure 7. FAK is a potent therapeutic target in human DGC cell lines and patients.
A, Immunoblots from IGC cell lines: AGS, KE39,YCC-1 and SNU719, and DGC lines 
SNU668, NUGC4 and FU97 (n = 3 independent experiments). B, Quantification of pFAK 
levels from (A). C, Representative immunoblots of FU97,SNU668 and SNU719 cells treated 
for 24 h with DMSO or FAK inhibitor PF-573228 (5 μM) or defactinib (2.5 μM) (n = 3 
independent experiments). D, In vitro proliferation of SNU668, NUGC4 and FU97 cells 
treated for indicated days with DMSO or PF-573228 (5 μM). Data are mean ± S.E.M. 
****P<0.0001, two-way ANOVA. E, In vitro proliferation of SNU719 and AGS cells 
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treated for the indicated days with DMSO or PF-573228 (5 μM). Data are mean ± S.E.M. 
****P<0.0001, two-way ANOVA. F, Tumor volume of 1✕106 SNU668 cells injected into 
flanks of NSG mice and treated with DMSO (n=4) or 5-FU (n=4, 50 mg/kg) or PF-573228 
(n=6, 12.5 mg/kg) every other day, with representative images (bottom) of tumors from each 
group. *P<0.05, ****P<0.0001, two-way ANOVA (Treatments versus DMSO). Data are 
mean ± S.E.M. G, Representative images of H&E of tumors from panel (F). Scale bar = 100 
μm. H, Tumor volume of 1✕106 SNU719 cells injected into flanks of NSG mice and treated 
with DMSO (n=4) or 5-FU (n=5, 50 mg/kg) or PF-573228 (n=4, 12.5 mg/kg) every other 
day. ns, not significant, ****P<0.0001, two-way ANOVA (Treatment versus DMSO). Data 
are mean ± S.E.M. I, Representative images of pFAK staining for human diffuse gastric 
patients with tumor area (left), adjacent normal surface epithelial area (middle) and gland 
epithelial cells (right). Scale bar = 100 μm.
Zhang et al. Page 35
Cancer Discov. Author manuscript; available in PMC 2020 August 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
